Beam Therapeutics (BEAM) Financial Statements & Analysis

Beam Therapeutics (BEAM) Income Statement

Beam Therapeutics reported revenue of $139.74M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 120.0% from $63.52M a year earlier. Beam Therapeutics posted a net loss of $79.99M, compared with a net loss of $376.74M a year earlier. Gross margin was 100.0% and operating margin -274.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $490.00K, down 94.2% from the same quarter a year earlier.

Beam Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Beam Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	139.74	63.52	377.71	60.92	51.84	0.02	0.02	0.00	0.00
Cost of Revenue	409.62	367.56	437.38	311.59	232.13	103.18	54.62	33.87	0.00
Gross Profit	139.74	-304.04	377.71	60.92	51.84	-103.16	-54.60	-33.87	0.00
Operating Expenses
Research & Development	409.62	367.56	437.38	311.59	387.09	103.18	54.62	33.87	5.86
Selling, General & Administrative	113.82	111.53	116.81	87.81	57.22	29.61	20.55	11.87	2.20
Operating Expenses	523.44	111.53	554.19	399.40	444.31	29.60	20.55	11.87	8.60
Operating Income	-383.69	-415.57	-176.49	-338.48	-392.47	-132.76	-75.15	-45.74	-8.60
Other Income/Expense
Interest Income	43.73	49.09	46.68	15.30	-0.01	1.57	2.49	0.29	0.00
Interest Expense	43.73	0.00	0.00	0.00	-0.01	0.00	0.19	0.00	0.00
Other Income/Expense	303.70	38.87	45.32	63.00	21.84	-61.83	-3.17	-71.00	-0.13
Income
Income Before Tax	-79.99	-376.70	-131.16	-260.18	-370.64	-194.59	-78.33	-116.74	-8.73
Income Tax Expense	0.00	0.04	-1.37	3.41	0.00	0.00	0.00	0.00	0.50
Net Income	-79.99	-376.74	-132.53	-289.09	-370.64	-194.59	-78.33	-115.26	-8.73
Net Income - Continuous Operations	-79.99	-376.74	-132.53	-289.09	-370.64	-194.59	-78.33	-115.26	-8.73
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-361.40	-354.78	-156.47	-315.90	-385.01	-128.03	-71.65	-45.09	-8.58
EBIT	-383.69	-415.57	-176.49	-338.48	-392.47	-132.76	-	-	-
Depreciation & Amortization	22.29	21.93	20.01	22.58	7.45	4.73	3.50	0.65	0.01
Earnings Per Share
Basic EPS	-1.00	-5.00	-2.00	-4.00	-6.00	-5.00	-2.00	-3.00	-1.00
Diluted EPS	-1.00	-5.00	-2.00	-4.00	-6.00	-5.00	-2.00	-3.00	-1.00
Basic Shares Outstanding	98.91	82.31	77.15	70.02	64.23	46.73	51.34	35.14	12.95
Diluted Shares Outstanding	98.91	82.31	77.15	70.02	64.23	46.73	51.34	35.14	12.95

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Beam Therapeutics Financial Statements

What was Beam Therapeutics's revenue in fiscal 2025?

Beam Therapeutics reported revenue of $139.74M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 120.0% from $63.52M a year earlier.

Is Beam Therapeutics profitable?

No. Beam Therapeutics reported a net loss of $79.99M in fiscal 2025. In fiscal 2024 it lost $376.74M.

What is Beam Therapeutics's operating margin?

Beam Therapeutics's operating income was −$383.69M on revenue of $139.74M in fiscal 2025, an operating margin of -274.6%, compared with -654.3% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition